Physician profile
Marion Guyer
NPI 1942388749
$840.07
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $65.55 · 2023: $373 · 2024: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $506.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $216.96 | 2019-2024 | Veozah |
| Amgen INC. | $143.05 | 2019-2024 | Prolia, Evenity |
| Novo Nordisk INC | $106.83 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Edwards Lifesciences Corporation | $61.99 | 2023 | |
| Merck Sharp & Dohme LLC | $50.63 | 2019-2020 | |
| Lilly USA, LLC | $42.90 | 2019-2023 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $42.19 | 2019-2020 | |
| Gilead Sciences, INC. | $38.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $32.04 | 2019 | |
| Radius Health, INC. | $29.89 | 2023 | Tymlos |
| Pfizer INC. | $26.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.19 | 2019 | |
| Ibsa Pharma INC. | $16.33 | 2023 | Tirosint, Licart |
| Sanofi Pasteur INC. | $14.69 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marion Guyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.